Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett Sells 42,975 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 42,975 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $78.61, for a total value of $3,378,264.75. Following the completion of the sale, the chief operating officer now directly owns 146,082 shares in the company, valued at approximately $11,483,506.02. The trade was a 22.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Roger Adsett also recently made the following trade(s):

• On Thursday, February 6th, Roger Adsett sold 45,605 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $3,689,444.50.
• On Tuesday, January 14th, Roger Adsett sold 1,457 shares of Insmed stock. The shares were sold at an average price of $68.72, for a total transaction of $100,125.04.
• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The stock was sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Stock Performance

Shares of INSM stock opened at $79.60 on Thursday. The company’s fifty day moving average price is $73.15 and its two-hundred day moving average price is $73.16. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a market capitalization of $14.24 billion, a P/E ratio of -14.34 and a beta of 1.11. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $82.04.

Analyst Ratings Changes

Several research analysts recently weighed in on INSM shares. Guggenheim increased their target price on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Stifel Nicolaus raised their price objective on Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. boosted their target price on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and an average target price of $85.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of INSM. Steward Partners Investment Advisory LLC increased its holdings in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of Insmed during the third quarter worth approximately $30,000. GAMMA Investing LLC increased its stake in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares during the last quarter. Spire Wealth Management acquired a new stake in Insmed in the fourth quarter valued at $47,000. Finally, Exchange Traded Concepts LLC boosted its stake in Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.